The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: Correlation with cognitive and functional decline

Behavioural Neurology

Volumn 18, Issue 4, 2007, Pages 207-215

  Öztürk, Candan ^a   Özge, Aynur ^a   Yalin, Osman Özgür ^a   Yilmaz, I Arda ^a   Delialioglu, Nuran ^a   Yildiz, Çilem ^a   Tesdelen, Bahar ^a   Kudiaki, Cigdem ^a  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Alzheimer's disease (AD); Cognitive decline; Cytokine; Functional decline; Inflammatory; Mild cognitive impairment (MCI); Soluble protein; Vascular dementia (VD)

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; CYTOKINE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL DISEASE; HUMAN; LABORATORY TEST; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 42049111225     PISSN: 09534180     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/432190     Document Type: Article

References (77)

1. C.R. Abraham, D.J. Selkoe and H. Potter, Immunochemical identification of the serine protease inhibitor alpha 1- antichymotrypsin in the brain amyloid deposits of Alzheimer's disease, Cell 52 (1988), 487-501.
2. C.R. Abraham, Reactive astrocytes and α1-antichymotrypsin in Alzheimer's disease, Neurobiology of Aging 22 (2001), 931-936.
3. P.S. Aisen, Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies, Gerontology 43 (1997), 143-149.
4. I. Akiguchi, H. Tomimoto, T. Suenaga, H. Wakita and H. Budka, Alterations in glia and axons in the brains of Binswanger's disease patients, Stroke 28 (1997), 1423-1429.
5. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole et al., Inflammation and Alzheimer's disease, Neurobiology of Aging 21 (2000a), 383-421.
6. P. Angelis, S. Scharf, A. Mander, F. Vajda and N. Christophidis, Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease, Neurosci Lett 244 (1998), 106-108.
7. M. Bagli, A. Papassotiropoulos, H. Hampel, K. Becker, F. Jessen, K. Burger et al., Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease, European Archives of Psychiatry and Clinical Neuroscience 253 (2003), 44-48.
8. A.A. Beharka, M. Meydani, D. Wu, L.S. Leka, A. Meydani and S.N. Meydani, Interleukin-6 production does not increase with age, Journals of Gerontology, Series A, Biological Sciences and Medical Sciences 56 (2001), 81-88.
9. D. Blum-Degen, T. Muller, W. Kuhn, M. Gerlach, H. Przuntek and P. Riederer, Interleukin-1? and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients, Neurosci Lett 20, (1995), 202-217.
10. S. Bonaccorso, A. Lin, C. Song, R. Verkerk, G. Kenis, E. Bosmans et al., Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT, Aging (Milano) 10 (1998), 316-323.
11. R. Cacabelos, X.A. Alvarez, L. Fernandez-Novoa, A. Franco, R. Mangues, A. Pellicer and T. Nishimura, Brain interleukin-1 beta in Alzheimer's disease and vascular dementia, Methods Find Exp Clin Pharmacol 16(2) (1994), 141-151.
12. D. Conn and L. Thorpe, Assessment of behavioural and psychological symptoms associated with dementia, Can J Neurol Sci 34(Suppl 1) (2007), S67-71.
13. A. De Luigi, C. Fragiacomo, U. Lucca, P. Quadri, M. Tettamanti and M. Grazia De Simoni, Inflammatory markers in Alzheimer's disease and multi-infarct dementia, Mech Ageing Dev 122(16) (2001), 1985-1995.
14. G. Del Zoppo, I. Ginis, J.M. Hallenbeck, C. Iadecola, X. Wang and G.Z. Feuerstein, Inflammation and stroke: putative role for cytokine adhesion molecules and iNOS in brain response to ischemia, Brain Pathol 112 (2000), 10-95.
15. R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul and D.M. Holtzman, Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease, Science 295 (2002), 2264-2267.
16. D.W. Dickson, S.C. Lee, L.A. Mattiace, S.H. Yen and C. Brosnan, Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease, Glia 7(1) (1993), 75-83.
17. S.T. Dinsmore, Alzheimer's disease diagnosis, J Am Osteopath Assoc Supply 99 (1999), S1-S6.
18. E. Esumi, S. Araga and K. Takahashi, Serum interleukin-2 levels in patients with dementia of the Alzheimer type, Acta Neurol Scand. 84(1) (1991), 65-67.
19. M. Fiala, L. Zhang, X. Gan, B. Sherry, D. Taub, M.C. Graves et al., Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model, Mol Med 4(7) (1998), 480-489.
20. H. Fukumoto, M. Tennis, J.J. Locascio, B.T. Hyman, J.H. Growdon and M.C. Irizarry, Age but not diagnosis is the main predictor of plasma amyloid β-protein levels, Arch Neurol 60 (2003), 958-964.
21. W.S. Griffin, J.G. Sheng, M.C. Royston, S.M. Gentleman, J.E. McKenzie, D.I. Graham, G.W. Roberts and R.E. Mrak, Glialneuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression, Brain Pathol 8(1) (1998), 65-72.
22. C.P. Hughes, L. Berg, W.L. Danziger, L.A. Coben and R.L. Martin, A new clinical scale for the staging of dementia, British Journal of Psychiatry 140, 566-572;
23. updated by Morris J (1993) The CDR: current version and scoring rules, Neurology 43 (1982), 2412-2413.
24. M.C. Irizarry, Biomarkers of Alzheimer disease in plasma, NeuroRx 1(2) (2004), 226-234.
25. J.P. Jia, R. Meng, Y.X. Sun, W.J. Sun, X.M. Ji and L.F. Jia, Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia, Neurosci Lett 383(1-2) (2005), 12-622-29.
26. J. Kalman, A. Juhasz, G. Laird, P. Dickens, T. Jardanhazy, A. Rimanoczy et al., Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease, Acta Neurol Scand 96 (1996), 236-240.
27. M.I. Kamboh, D.K. Sanghera, R.E. Ferrell and S.T. DeKosky, APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism, Nat Genet 10(4) (1995), 486-488. Erratum in: Nat Genet 11(1) (1995), 104.
28. A.S. Lanzrein, C.M. Johnston, V.H. Perry, K.A. Jobst, E.M. King and A.D. Smith, Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor- alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin, Alzheimer Dis Assoc Disord 12(3) (1998), 215-227.
29. M.P. Lawton and E.M. Brody, Assessment of older people: self-maintaining and instrumental activities of daily living, The Gerontologist 9 (1969), 179-186.
30. B. Leveugle and H. Fillit, Proteoglycans and the acute-phase response in Alzheimer's disease brain, Mol Neurobiol 9(1-3) (Aug-Dec. 1994), 25-32.
31. H.L. Li, N. Kostulas, Y.M. Huang et al., IL-17 and IFNgamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat, J Neuroimmunol 116 (2001), 5-14.
32. 1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 103 (2000), 97-102.
33. C. Lindberg, M. Chromek, L. Ahrengart, A. Brauner, M. Schultzberg and A. Garlind, Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease, Neurochem Int 46(7) (2005), 551-557.
34. C. Loeb and C. Gandolfo, Diagnostic evaluation of degenerative and vascular dementia, Stroke 14 (1983), 399-401.
35. K. Maiese and Z.Z. Chong, Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease, Restor Neurol Neurosci 22 (2004), 87-104.
36. R. Mayeux, M.X. Tang, D.M. Jacobs, J. Manly, K. Bell, C. Merchant et al., Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease, Ann Neurol 46 (1999), 412-416.
37. P.L. McGeer, T. Kawamata, D.G. Walker, H. Akiyama, I. Tooyama and E.G. McGeer, Microglia in degenerative neurological disease, Glia 7 (1993), 84-92.
38. E.G. McGeer and P.L. McGeer, Brain inflammation in Alzheimer disease and the therapeutic implications, Curr Pharm Des 5(10) (1999), 821-836.
39. P.L. McGeer and E.G. McGeer, Polymorphisms in inflammatory genes enhance the risk of Alzheimer disease, Arch Neurol 58 (2001), 1790-1792.
40. E.G. McGeer and P.L. McGeer, Inflammatory processes in Alzheimer's disease, Prog Neuropsychopharmacol Biol Psychiatry 27(5) (2003), 741-749.
41. G. McKhann, D. Drachman, M. Folstein, K. Katzman, D. Price and E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34 (1984), 939-944.
42. P.D. Mehta, T. Pirttila, S.P. Mehta, E.A. Sersen, P.S. Aisen and H.M. Wisniewski, Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease, Arch Neurol 57 (2000), 100-105.
43. P.D. Mehta, T. Pirttila, B.A. Patrick, M. Barshatzky and S.P. Mehta, Amyloid β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease, Neurosci Lett 304 (2001), 102-106.
44. D.W. Molloy, E. Alemayehu and R. Roberts, Reliability of standardized mini-mental state examination compared with traditional mini-mental state examination, American Journal of Psychiatry 148 (1991), 102-105.
45. R.E. Mrak, J.G. Sheng and W.S. Griffin, Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease, J Neuropathol Exp Neurol 55(3) (1996), 273-279.
46. A.H. Moore and M.K. O'Banion, Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease, Advanced Drug Delivery Reviews 54 (2002), 1627-1656.
47. Neuroinflammation Working Group. Inflammation and Alzheimer's disease, Neurobiol Aging 21 (2000), 383-421.
48. L.N.G. Nilsson, S. Das and H. Potter, Effect of cytokines, dexamethazone and the A/T-signal peptide polymorphism on the expression of alpha1-antichymotrypsin in astrocytes: significance for Alzheimer's disease, Neurochemistry International 39 (2001), 361-370.
49. H. Okamura, H. Tsutsui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto et al., Cloning of a new cytokine that induces IFN-g production by T-cells, Nature 378 (1995), 88-91.
50. R. Paganelli, A. Di Iorio, L. Patricelli, F. Ripani, E. Sparvieri, R. Faricelli et al., Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients, Exp Gerontol 37(2-3) (2002), 257-263.
51. A. Papassotiropoulos, M. Bagli, F. Jessen, T.A. Nayer, W. Maier, M.L. Rao and R. Heun, A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease, Ann Neurol 45 (1999), 666-668.
52. J.M. Pasternack, C.R. Abraham, B.J. Van Dyke, H. Potter and S.G. Younkin, Astrocytes in Alzheimer's disease gray matter express alpha1- antichymotrypsinmRNA, American Journal of Pathology 125 (1989), 827-834.
53. L.S. Perlmutter, E. Barron and H.C. Chui, Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease, Neurosci Lett 119 (1990), 32-36.
54. A.C. Petersen, J.C. Stevens, M. Ganguli et al., Practice parameter: early detection of dementia: mild cognitive impairment (an-evidence based review). Report of the Quality Standards Subcommittee of the America Academy of Neurology 56 (2001), 1133-1142.
55. B. Reisberg, S.H. Ferris, M.J. de Leon and T. Crook, The global Deterioration Scale (GDS) for assessment of primary degenerative dementia, American Journal of Psychiatry 139 (1982), 1136-1139.
56. E. Richartz, E. Stransky, A. Batra, P. Simon, P. Lewczuk, G. Buchkremer et al., Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease? J Psychiatr Res 39(5) (2005), 535-543.
57. G.C. Roman, T.K. Tatemichi, T. Erkinjuntti, J.L. Cummings, J.C. Masdeu, J.H. Garcia et al., Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop, Neurology 43 (1993), 250-260.
58. G. Sala, G. Galimberti, C. Canevari, M.E. Raggi, V. Isella, M. Facheris et al., Peripheral cytokine release in Alzheimer patients: correlation with disease severity, Neurobiol Aging 24(7) (2003), 909-914.
59. V.K. Singh and P. Guthikonda, Circulating cytokines in Alzheimer's disease, J Psychiatr Res 31 (1997), 657-660.
60. J. Tan, T. Town, D. Paris, T. Mori, Z. Suo, F. Crawford et al., Microglial activation resulting from CD40-CD40L interaction after β-amyloid, Science 286 (1999), 2352-2355.
61. E. Tarkowski, K. Blennow, A. Wallin and A. Tarkowski, Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia, J Clin Immunol 19 (1999), 223-230.
62. E. Tarkowski, A. Wallin, B. Regland, K. Blennow and A. Tarkowski, Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia, Acta Neurol Scand 103 (2001), 166-174.
63. E. Tarkowski, N. Andreasen, A. Tarkowski and K. Blennow, Intrathecal inflammation precedes development of Alzheimer's disease, J Neurol Neurosurg Psychiatry 74(9) (2003), 1200-1205.
64. C.E. Teunissen, J. de Vente, H.W. Steinbusch and C. De Bruijn, Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid, Neurobiol Aging 23(4) (2002), 485-508.
65. E.E. Tuppo and H.R. Arias, The role of inflammation in Alzheimer's disease, Int J Biochem Cell Biol 37(2) (2005), 289-305.
66. H. Vanderstichele, E. Van Kerschaver, C. Hesse, P. Davidsson, M.A. Buyse, N. Andreasen et. al. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma, Amyloid 258 (2000), 245-247.
67. N. Vila, J. Castillo, A. Davalos and A. Chamorro, Proin-flammatory cytokines and early neurological worsening in ischemic stroke, Stroke 31 (2000), 2325-2329.
68. K. Wada-Isoe, Y. Wakutani, K. Urakami and K. Nakashima, Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients, Acta Neurol Scand 110 (2004), 124-127.
69. M.N.Wallace, J.G. Geddes, D.A. Farquhar and M.R. Masson, Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques, Exp Neurol 144(2) (1997), 266-272.
70. D.M. Walsh and D.J. Selkoe, Deciphering the molecular basis of memory failure in Alzheimer's disease, Neuron 44(1) (2004), 181-193.
71. J.D. Weaver, M.H. Huang, M. Albert, T. Harris, J.W. Rowe and T.E. Seeman, Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging, Neurology 59(3) (2002), 371-378.
72. H.L. Weiner and D.J. Selkoe, Inflammation and therapeutic vaccination in CNS diseases, Nature 420 (2002), 879-884.
73. C.J. Wilson, C.E. Finch and H.J. Cohen, Cytokines and cognition-the case for a head-to-toe inflammation paradigm, Journal of the American Geriatric Society 50 (2002), 2041-2056.
74. M.Q. Xia and B.T. Hyman, Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease, J Neurovirol 5(1) (1999), 32-41.
75. K. Yasojima, C. Schwab, E.G. McGeer and P.L. McGeer, Up-regulation and activation of the complement system in the Alzheimer's disease brain, American Journal of Pathology 154 (1999), 927-936.
76. I. Yatsiv, M.C. Morganti-Kossman, D. Perez, C.A. Dinarello, D. Novick, M. Rubinstein et al., Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury, J Cereb Blood Flow Metab 22 (2002), 971-978.
77. B. Yucesoy, R. Peila, L.R. White, K.M. Wu, V.J. Johnson, M.L. Kashon et al., Association of interleukin-1 gene polymorphisms with dementia in a community-based sample: the Honolulu-Asia Aging Study, Neurobiol Aging 27(2) (2006), 211-217.